Development of severe sclerotic chronic GVHD during treatment with dasatinib

Bone Marrow Transplantation

Volumn 45, Issue 9, 2010, Pages 1469-1470

  Pulanic, D ^a   Cowen, E W ^a   Baird, K ^a   Bishop, M R ^a   Pavletic, S Z ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; DASATINIB; IMATINIB; IMMUNOGLOBULIN; PREDNISONE; RAPAMYCIN; RITUXIMAB; TACROLIMUS;

ADULT; BONE MARROW TRANSPLANTATION; CASE REPORT; CHRONIC GRAFT VERSUS HOST DISEASE; CHRONIC MYELOID LEUKEMIA; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; DRUG WITHDRAWAL; FIBROSIS; GRAFT VERSUS HOST REACTION; HUMAN; LETTER; LIVER DISEASE; LOW DRUG DOSE; MALE; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PHILADELPHIA CHROMOSOME POSITIVE CELL; PRIORITY JOURNAL; PURE RED CELL ANEMIA; REDUCED INTENSITY CONDITIONING; SCLEROSIS; TREATMENT DURATION; TREATMENT RESPONSE;

CHRONIC DISEASE; COMBINED MODALITY THERAPY; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; PROTEIN KINASE INHIBITORS; PYRIMIDINES; SCLEROSIS; SEVERITY OF ILLNESS INDEX; THIAZOLES; YOUNG ADULT;

EID: 77956488450     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2009.368     Document Type: Letter

References (10)

1. Breccia M, Cannella L, Stefanizzi C, Carotti A, Santopietro M, Alimena G. Efficacy of dasatinib in a chronic myeloid leukemia patient with disease molecular relapse and chronic GVHD after haploidentical BMT: an immunomodulatory effect? [letter] Bone Marrow Transplant 2009; 44: 331-332.
2. Magro L, Catteau B, Coiteux V, Bruno B, Jouet JP, Yakoub-Agha I. Efficacy of imatinib mesylate in the treatment of refractory sclerodermatous chronic GVHD. Bone Marrow Transplant 2008; 42: 757-760.
3. Magro L, Mohty M, Catteau B, Coiteux V, Chevallier P, Terriou L et al. Imatinib mesylate as salvage therapy for refractory sclerotic chronic graft-versus-host disease. Blood 2009; 114: 719-722.
4. Olivieri A, Locatelli F, Zecca M, Sanna A, Cimminiello M, Raimondi R et al. Imatinib for refractory chronic graft-versus-host disease with fibrotic features. Blood 2009; 114: 709-718.
5. Stadler M, Ahlborn R, Kamal H, Diedrich H, Buchholz S, Eder M et al. Limited efficacy of imatinib in severe pulmonary chronic graft-versus-host disease [letter]. Blood 2009; 114: 3718-3719.
6. Aguilera DG, Tsimberidou AM. Dasatinib in chronic myeloid leukemia: a review. Ther Clin Risk Manag 2009; 5: 281-289.
7. Akhmetshina A, Dees C, Pileckyte M, Maurer B, Axmann R, Jungel A et al. Dual inhibition of c-abl and PDGF receptor signaling by dasatinib and nilotinib for the treatment of dermal fibrosis. FASEB J 2008; 22: 2214-2222.
8. Skhirtladze C, Distler O, Dees C, Akhmetshina A, Busch N, Venalis P et al. Src kinases in systemic sclerosis: central roles in fibroblast activation and in skin fibrosis. Arthritis Rheum 2008; 58: 1475-1484.
9. Daniels CE, Wilkes MC, Edens M, Kottom TJ, Murphy SJ, Limper AH et al. Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis. J Clin Invest 2004; 114: 1308-1316.
10. Schade AE, Schieven GL, Townsend R, Jankowska AM, Susulic V, Zhang R et al. Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation. Blood 2008; 111: 1366-1377.